CLAIMS

1. A gastro-resistant pharmaceutical composition comprising (a) dimethyl fumarate, (b) a diluent selected from fructose, lactose, dibasic calcium phosphate, mannitol, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the composition is coated with a coating comprising triethyl citrate.

2. A gastro-resistant pharmaceutical composition according to claim 1, wherein the dimethyl fumarate is not covered with a gastro-resistant coating.

3. A pharmaceutical composition according to any one of claims 1 or 2, comprising (a) dimethyl fumarate, (b) lactose, (c) microcrystalline cellulose and (d) croscarmellose sodium.

4. A pharmaceutical composition according to any one of claims 1 to 3, further comprising (e) at least one glidant.

5. A pharmaceutical composition according to claim 4, wherein the glidant (e) is selected from calcium phosphate, calcium silicate, powdered cellulose, magnesium silicate, magnesium trisilicate, silicon dioxide, talc, colloidal silica, colloidal anhydrous silica and mixtures thereof.

6. A pharmaceutical composition according to any one of claims 1 to 5, further comprising (f) at least one lubricant.

7. A pharmaceutical composition according to claim 6, wherein the lubricant (f) is selected from magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, sodium benzoate, potassium benzoate, light mineral oil, hydrogenated

vegetable oils, glycerin monostearate, glyceryl behenate, glyceryl palmitostearate, stearic acid, zinc stearate, and mixtures thereof.

8. A pharmaceutical composition according to any one of claims 1 to 7, wherein the weight ratio (c) microcrystalline cellulose to (b) diluent is in the range from 2:5 to 5:2.

9. A pharmaceutical composition according to any one of claims 1 to 8, wherein the composition is administered orally.

10. A pharmaceutical composition according to any one of claims 1 to 9 in the form of tablet.

11. A pharmaceutical composition according to claim 10 comprising, based on the total weight of the tablet previous to coating:

(a) 20-30 wt.% of dimethyl fumarate;

(b) 25-35 wt.% of a diluent selected from lactose, fructose, dibasic calcium phosphate, mannitol, and mixtures thereof;

(c) 35-45 wt.% of microcrystalline cellulose;

(d) 1-10 wt.% of croscarmellose sodium.

12. A pharmaceutical composition according to claim 11 further comprising (e) at least one glidant.

13. A pharmaceutical composition according to claim 11 or claim 12 further comprising (f) at least one lubricant.

14. A pharmaceutical composition according to any one of claims 11 to 13 comprising, based on the total weight the tablet previous to coating:

(a) 25 wt.% of dimethyl fumarate;

(b) 30 wt.% of lactose;

(c) 40 wt.% of microcrystalline cellulose;

(d) 4 wt.% of croscarmellose sodium;

(e) 0.5 wt.% of at least one glidant;

(f) 0.5 wt.% at least one lubricant.

15. A pharmaceutical composition as defined in any one of claims 1 to 14 for use in the treatment or prevention of inflammatory or autoimmune diseases or disorders, in particular inflammatory or autoimmune diseases or disorders selected from rheumatoid arthritis, multiple sclerosis (MS), amyotrophic lateral sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), myasthenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, Sjogren's syndrome, autoimmune hemolytic anemia (AIHA), type I diabetes or psoriasis.

16. Use of a pharmaceutical composition as defined in any one of claims 1 to 14 for the manufacture of a medicament for the treatment or prevention of inflammatory or autoimmune diseases or disorders, in particular inflammatory or autoimmune diseases or disorders selected from rheumatoid arthritis, multiple sclerosis (MS), amyotrophic lateral sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), myasthenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, Sjogren's syndrome, autoimmune hemolytic anemia (AIHA), type I diabetes or psoriasis.